scholarly journals Nuclear Medicine Imaging in the Pediatric Patient

2006 ◽  
Vol 11 (4) ◽  
pp. 200-211
Author(s):  
Vivian Loveless
Keyword(s):  
Nuclear Medicine ◽  
Pediatric Patients ◽  
Radiation Safety ◽  
Endocrine System ◽  
Nuclear Medicine Imaging ◽  
Safety Issues ◽  
Disease States ◽  
Pulmonary System ◽  
Pediatric Nuclear Medicine ◽  
The Central Nervous System

Pediatric nuclear medicine provides a wealth of information on a variety of disease states; however, precautions on dosing have to be taken into consideration. Also, expertise in conducting procedures and interpreting the results in pediatric patients is necessary. Emphasis is placed on diagnostic studies involving the central nervous system, musculoskeletal system, genitourinary system, gastrointestinal system, endocrine system, pulmonary system, and cardiovascular system along with a brief explanation of the mechanism of localization of the radiopharmaceuticals involved. Radiation safety issues are addressed when the expectant mother or nursing mother is administered radiopharmaceuticals.

scholarly journals Manual on the proper use of yttrium-90-labeled anti-P-cadherin antibody injection for radionuclide therapy in clinical trials

2019 ◽  
Vol 33 (11) ◽  
pp. 787-805 ◽  
Author(s):  
Makoto Hosono ◽  
Hideharu Ikebuchi ◽  
Seigo Kinuya ◽  
Sachiko Yanagida ◽  
Yoshihide Nakamura ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Nuclear Medicine ◽  
Radiation Protection ◽  
Radionuclide Therapy ◽  
Japanese Society ◽  
Radiation Safety ◽  
Japanese Version ◽  
Ministry Of Health ◽  
Safety Issues ◽  
Yttrium 90

Abstract We present the guideline for use of yttrium-90-labeled anti-P-cadherin antibody injection for radionuclide therapy in clinical trials on the basis of radiation safety issues in Japan. This guideline was prepared by a study supported by the Ministry of Health, Labour, and Welfare, and approved by the Japanese Society of Nuclear Medicine. Treatment using yttrium-90-labeled anti-P-cadherin antibody injection in Japan should be carried out according to this guideline. Although this guideline is applied in Japan, the issues for radiation protection shown here are considered internationally useful as well. Only the original Japanese version is the formal document.

Why Wasn't Radionuclide Diagnosis of Bleeding Meckel's Diverticulum Mentioned?

PEDIATRICS ◽  
1977 ◽  
Vol 60 (6) ◽  
pp. 940-940
Author(s):  
Arnold Schussheim ◽  
Gerard Moskowitz ◽  
Lester Levy
Keyword(s):  
Nuclear Medicine ◽  
Preoperative Diagnosis ◽  
Pediatric Patients ◽  
Meckel’S Diverticulum ◽  
Meckel's Diverticulum ◽  
American Academy Of Pediatrics ◽  
Radionuclide Diagnosis ◽  
Pediatric Nuclear Medicine ◽  
Standard Techniques ◽  
The Ideal

The article on pediatric nuclear medicine by the Committee on Radiology of the American Academy of Pediatrics (Pediatrics 58:459, September 1976) had as its intention to update "the expanding role that radionuclide techniques have in the management of pediatric patients." It also noted the ideal properties of technetium 99m for imaging. It did not, however, include any mention of its use in the preoperative diagnosis of bleeding Meckel's diverticulum in children. Rectal bleeding in children due to Meckel's diverticulum is not uncommon, it is often massive, and the failure of standard techniques to make this diagnosis is well known.

scholarly journals Optimization of Low-Dose CT Protocol in Pediatric Nuclear Medicine Imaging

2010 ◽  
Vol 38 (4) ◽  
pp. 181-185 ◽  
Author(s):  
H. Piwowarska-Bilska ◽  
L. J. Hahn ◽  
B. Birkenfeld ◽  
K. Cichon-Bankowska ◽  
M. H. Listewnik ◽  
...  
Keyword(s):  
Nuclear Medicine ◽  
Low Dose ◽  
Nuclear Medicine Imaging ◽  
Low Dose Ct ◽  
Ct Protocol ◽  
Pediatric Nuclear Medicine

Pediatric Nuclear Medicine

PEDIATRICS ◽  
1976 ◽  
Vol 58 (3) ◽  
pp. 459-461
Author(s):  
Herman Grossman ◽  
Alvin Felman ◽  
John Kirkpatrick ◽  
Charles E. Shopfner ◽  
Leonard E. Swischuk ◽  
...  
Keyword(s):  
Nuclear Medicine ◽  
Rapid Growth ◽  
Growth And Development ◽  
Pediatric Patients ◽  
Imaging Techniques ◽  
Bone Imaging ◽  
Nuclear Techniques ◽  
Pediatric Nuclear Medicine ◽  
Direct Radionuclide Cystography ◽  
99Mtc Radiopharmaceuticals

The subspecialty of pediatric nuclear medicine has rapidly developed since the last discussion1 of the indications for and value of radionuclide imaging in children. New imaging techniques, equipment, and radiopharmaceuticals have stimulated this rapid growth. Bone imaging with the 99mTc phosphate compounds has been applied to evaluate benign as well as malignant processes. Tumor detection and staging have been accomplished with various 99mTc radiopharmaceuticals. Vesicoureteral reflux is more effectively detected with direct radionuclide cystography. A major role in the detection and evaluation of cardiac abnormalities and shunts has been achieved with nuclear techniques. Recognition of this remarkable growth and development is found in the publication of several books on pediatric nuclear medicine, the presentation of pediatric nuclear in medicine seminars, and formal sessions at the Society of Nuclear Medicine annual meeting.2-6 This brief discussion will hopefully keep the pediatrician aware of the expanding role that radionuclide techniques have in the management of pediatric patients.

Patients with fever of unknown origin (FUO): diagnosis by nuclear medicine imaging

2001 ◽  
Vol 40 (03) ◽  
pp. 59-70 ◽  
Author(s):  
W. Becker ◽  
J. Meiler
Keyword(s):  
Nuclear Medicine ◽  
Fever Of Unknown Origin ◽  
Tumor Imaging ◽  
White Blood Cells ◽  
Unknown Origin ◽  
Final Diagnosis ◽  
Recurrent Fever ◽  
Nuclear Medicine Imaging

SummaryFever of unknown origin (FUO) in immunocompetent and non neutropenic patients is defined as recurrent fever of 38,3° C or greater, lasting 2-3 weeks or longer, and undiagnosed after 1 week of appropriate evaluation. The underlying diseases of FUO are numerous and infection accounts for only 20-40% of them. The majority of FUO-patients have autoimmunity and collagen vascular disease and neoplasm, which are responsible for about 50-60% of all cases. In this respect FOU in its classical definition is clearly separated from postoperative and neutropenic fever where inflammation and infection are more common. Although methods that use in-vitro or in-vivo labeled white blood cells (WBCs) have a high diagnostic accuracy in the detection and exclusion of granulocytic pathology, they are only of limited value in FUO-patients in establishing the final diagnosis due to the low prevalence of purulent processes in this collective. WBCs are more suited in evaluation of the focus in occult sepsis. Ga-67 citrate is the only commercially available gamma emitter which images acute, chronic, granulomatous and autoimmune inflammation and also various malignant diseases. Therefore Ga-67 citrate is currently considered to be the tracer of choice in the diagnostic work-up of FUO. The number of Ga-67-scans contributing to the final diagnosis was found to be higher outside Germany than it has been reported for labeled WBCs. F-l 8-2’-deoxy-2-fluoro-D-glucose (FDG) has been used extensively for tumor imaging with PET. Inflammatory processes accumulate the tracer by similar mechanisms. First results of FDG imaging demonstrated, that FDG may be superior to other nuclear medicine imaging modalities which may be explained by the preferable tracer kinetics of the small F-l 8-FDG molecule and by a better spatial resolution of coincidence imaging in comparison to a conventional gamma camera.

scholarly journals Manual on the proper use of sodium astatide ([211At]NaAt) injections in clinical trials for targeted alpha therapy (1st edition)

2021 ◽  
Author(s):  
Tadashi Watabe ◽  
Makoto Hosono ◽  
Seigo Kinuya ◽  
Takahiro Yamada ◽  
Sachiko Yanagida ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Japanese Society ◽  
Radiation Safety ◽  
Safety Management ◽  
Evaluation Methodology ◽  
Targeted Alpha Therapy ◽  
Safety Issues ◽  
Safety Standards ◽  
And Training ◽  
Alpha Therapy

AbstractWe present the guideline for use of [211At] sodium astatide (NaAt) for targeted alpha therapy in clinical trials on the basis of radiation safety issues in Japan. This guideline was prepared by a study supported by the Ministry of Health, Labour, and Welfare, and approved by the Japanese Society of Nuclear Medicine on 8th Feb, 2021. The study showed that patients receiving [211At]NaAt do not need to be admitted to a radiotherapy room and outpatient treatment is possible. The radiation exposure from the patient is within the safety standards of the ICRP and IAEA recommendations for the general public and caregivers. Precautions for patients and their families, safety management associated with the use of [211At]NaAt, education and training, and disposal of medical radioactive contaminants are also included in this guideline. Treatment using [211At]NaAt in Japan should be carried out according to this guideline. Although this guideline is applied in Japan, the issues for radiation protection and evaluation methodology shown here are considered internationally useful as well.

Radiopharmaceuticals in Pediatric Nuclear Medicine

2020 ◽  
pp. 653-701
Author(s):  
Scott E. Snyder ◽  
Elizabeth R. Butch ◽  
Barry L. Shulkin
Keyword(s):  
Nuclear Medicine ◽  
Pediatric Nuclear Medicine
Sign in / Sign up

Export Citation Format

Share Document